- Home
- SFL vs ERAS Comparison
SFL vs ERAS Comparison
Compare SFL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFL | ERAS |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SFL | ERAS |
|---|---|---|
| Price | $8.05 | $3.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $11.00 | $3.71 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $774,521,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.73 | $1.01 |
| 52 Week High | $11.14 | $3.80 |
Technical Indicators
Market Signals| Indicator | SFL | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 59.88 |
| Support Level | $7.66 | $3.36 |
| Resistance Level | $7.84 | $3.77 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 78.71 | 72.22 |
Price Performance
Historical ComparisonAbout SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.